卡培他滨单药治疗晚期乳腺癌的临床研究

目的观察和评价卡培他滨单药治疗晚期复发转移性乳腺癌的临床疗效和毒性反应。方法 21例晚期复发转移性乳腺癌患者均经病理组织学和(或)细胞学检查确诊。给予单药卡培他滨2000 mg/(m2.d),分2次口服,连服2周,3周为1个周期。至少2个周期后评价疗效。21 d为1个周期,至少治疗2个周期。结果 21例患者均可评价,CR 1例,PR 6例,SD 8例,PD 6例,患者的近期有效率为33.4%、疾病控制率(CR+PR+SD)为71.4%(15/21),TTP、中位生存期及1年、2年生存率分别为5.1个月、13.2个月和50.1%、33.2%。常见不良反应为手足综合征(66.7%)、皮肤色素沉着(52.5%)、恶心、呕吐(28.6%)和腹泻15%,但均可以耐受。结论单药卡培他滨对复发转移性乳腺癌有较好的临床疗效,可改善患者的生存质量,延长生存时间,毒性反应比较轻,老年患者亦可以耐受。

Clinical study of capecitabine monotherapy in the treatment of advanced metastatic breast cancer

Objective Observing efficacy,toxicity and side effects of capecitabine monotherapy in the treatment of advanced metastatic breast cancer.Methods 21 cases of advanced metastatic breast cancer patients were treated with capecitabine 2000 mg/m2 orally twice a day for 2 weeks every 3 weeks.The efficacy was estimated after 2 cycles.Results Complete remisson(CR) was observed in 1 case and PR in 6 cases,SD in 8 cases,the response rate were 33.4%,The control rate(CR+PR+SD) was 71.4%(15/21),time to progress(TTP),med...